
OCT .0 e 2003 A THAT

PTO/SB/21 (03-03)

Li de the Renewatik Reduction Astro	1005		t and Trademark Offi	ce; U.S. Di	th 04/30/2003. OMB 0651-0031 EPARTMENT OF COMMERCE				
Charlet the Paderwork Reduction Act of	1995, no persons	are required to respond to a collection Application Number	10/608,200	SS IL UISDIA	vs a valid OwiB control number.				
TRANSMITTAL		Filing Date June 27,							
FORM		First Named Inventor	Jean-Marc Pa	al.					
(to be used for all correspondence after initial filin		Art Unit							
		Examiner Name							
Total Number of Pages in This Submiss	on	Attorney Docket Number	F-4066-DIV-0	ONT-D	IV II				
ENCLOSURES (Check all that apply)									
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s Extension of Time Request Express Abandonment Reque Information Disclosure Statem Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Funder 37 CFR 1.52 or	t Feman Other E - PTO-Return	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addre Ferminal Disclaimer Request for Refund CD, Number of CD(s) Enclosures: 1449 (4 Pages) In Postcard	to All All All All All All All All All Al	a Techno opeal Con Appeals opeal Con ppeal Noti coprietary	sure(s) (please				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT									
Firm or Individual Signature October 8, 2003		AT LICANT, ATTORN	LI, ON AGEN						
CERTIFICATE OF TRANSMISSION/MAILING EXPRESS MAIL NO. EV 321710352 US									
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as \$105,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope addressed to: Commissioner for Patents, \$200,000 in an envelope ad									
Typed or printed ARM#	NDO CH	ING							
Signature drn	NDO CH	b Chine			October 8, 2003				

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.





OT 0 8 2003 H

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

)

)

)

)

)

)

)

)

)

In re application of:
 Jean-Marc Payrat, et al.

Serial No.: 10/608,200

Filed: June 27, 2003

Examiner:

Art Unit:

For: RED BLOOD CELL COMPOSITION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

"Express Mail" Mailing Label: EV321710352US

Date of Deposit: October 8, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office Box Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NAME: ARMANDO CHUNG

SIGNATURE: drmato Chiz

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.97, Applicant hereby calls the Examiner's attention to documents listed on the attached form, which documents may be material to the examination of this application. Copies of each of the documents were provided by the Office or submitted by Applicants to the Patent Office in one (or more) of U.S. Serial No. 09/268,405, filed March 15, 1999, which is a continuation of Serial No. 08/742,229, filed October 31, 1996, which is a continuation of Serial No. 08/491, 099, filed June 16, 1995, which is a continuation of Serial No.

08/216,734, filed March 22, 1994, which is a divisional of Serial No. 07/610,478, filed November 7, 1990, which are being relied upon for an earlier filing date under 35 USC 120. Accordingly, pursuant to 37 C.F.R. §1.98(d), copies of the documents are not being submitted herewith. Copies of the two Board Decisions (references DN and DO on the attached List of Citations) were previously submitted with the application papers. If copies of any such documents are not available to the Examiner or are otherwise required, Applicant will gladly provide them.

No inference should be drawn that the attached list sets forth a comprehensive investigation of the prior art, that any or all are pertinent to the invention, or that any apparatus disclosed is equivalent to the subject invention.

The citation of the above-discussed documents is not to be construed as an assertion that more pertinent art could not possibly be in existence. Citation of any document herein is not to be construed as an admission that any subject matter disclosed in the document is necessarily within the inventive field of endeavor, that any disclosure is necessarily prior in time to a particular date which may be relevant to the instant patent application, and/or that any disclosure is otherwise necessarily prior art with respect to the instant invention.

Applicant also respectfully reserves the right to later set forth how the instant invention is distinguished over the disclosure of any document or other art, including the disclosure of those documents discussed herein, that may be cited by the Examiner in rejecting a claim in the instant patent application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Accordingly, it is believed that no fee under 37 CFR 1.97(c) is required. If it is determined that a fee is required for this Information Disclosure Statement, please charge our Deposit Account No. 50/1039.

Respectfully submitted,

Andrew G. Kolomayets

Registration No. 33,723

COOK, ALEX, MCFARRON, MANZO, CUMMINGS & MEHLER, LTD. 200 West Adams Street - #2850 Chicago, IL 60606 (312) 236-8500 OTPE TO 8 2003 A

37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT

(use several sheets if necessary)

Docket No. F-4066 DIV-CONT-DIV II 10/608,200

Applicant Payrat et al.

Filing Date
June 27, 2003

Group Art Unit Unknown

					June 2	7, 2003	Uп	known
	 -	U.	S. PATENT	DOCUMENTS				
Examiner's Initials		Document Number	Date	Name ·	Class	Subclass		ng Da
	AA	Re. 32,874	02/21/89	Rock et al.			1	
	AB	4,082,509	04/04/78	Talcott			_	
	AC	4,222,379	09/16/80	Smith			†	<u>-, -, - , - , - , - , - , - , - , - , -</u>
	AD	4,267,269	05/12/81	Grode et al.			1	
	AE	4,356,172	10/26/82	Nakao et al.			+-	
	AF	4,572,899	02/25/86	Walker et al.		·	†	
·	AG	4,585,735	04/29/86	Meryman et al.			1	
	AH	4,608,178	08/26/86	Johansson et al.			_	
	AI	4,675,185	06/23/87	Kandler et al.			_	
	AJ	4,695,460	09/22/87	Holme			au	
	AK	4,704,352	11/03/87	Miripol et al.			 	
		FORE	IGN PATEN	T DOCUMENTS	-		<u></u>	
							Translation	
		Document Number	Date	Country	Class	Subclass	Yes	No
	AL	WO 81/02239	08/20/81	PCT				
	AM	100 419	02/15/84	Europe				
	AN	0 044 864	06/05/85	Europe				
	AO	WO 86/00809	02/13/86	PCT				
	AP	WO 88/1871	03/24/88	PCT				
	O'	THER ART (Includin	g Author, I	Title, Date, Pertine	ent Pages,	Etc.)	·	
	AQ	Asakuta et al., "pH de Clin. Chim. Acta, Vol	pendency of . 14, 1966, p	2,3-diphosphoglyc p. 840-841.	erate conti	ent in red bloo	od cells	,",
	AR	Bessis, "Red Cell Sha Française d'Hématolo	pes. An Illus gie, Vol. 12,	strated Classification, No. 6, 1972, pp. 7	n and Its F 21-746.	Rationale", No	uvelle	Revu
	AS	Bartlett, "Use of Adenine in Blood Making", Laboratory for Comparative Biochemistry, pp. 347-350.						
	AT	Beutler, "Viability, Fu	inction, and l	Rejuvenation of Lig	wid-Store	Red Cells"	nn 194	5-213
	AU	Beutler et al., "Deplete Blood Cells", Transfus	ion and Rege	neration of 2,3-dipl	hosphogly			
	AV	Beutler, "Experimenta				nn 189-216		
xaminer			Date Consid			PP. 107-210.		

*EXAMINED: Initial if reference considered substant as an an

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citati n if not in conformance and not considered. Include copy of this form with next communicati n t applicant.

OT D 8 2003 B

Examiner

37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT

(use several sheets if necessary)

Docket No.
F-4066 DIV-CONT-DIV II 10/608,200

Applicant
Payrat et al.

Filing Date Group Art Unit Unknown June 27, 2003 U.S. PATENT DOCUMENTS Examiner's Filing Date Initials Document Number If appropriate Date Name Class Subclass 09/06/88 Hamasaki et al. BA 4,769,318 BB 4,812,310 03/14/89 Sato et al. 05/09/89 BC 4,828,976 Murphy BD 4,838,861 06/13/89 Sharp BE 4,850,993 07/25/89 Champion et al. BF 4,880,786 11/14/89 Sasakawa et al. 12/26/89 BG 4,889,943 Kawamura et al. BH 4,892,537 01/09/90 Carmen et al. BI 02/20/90 4,902,287 Carmen et al. BJ 4,961,928 10/09/90 Holme et al. BK 4,969,882 Carmen et al. 11/13/90 FOREIGN PATENT DOCUMENTS **Translation** Country Document Number Date Class Subclass Yes No BL 0 301 250 06/28/88 Europe BM 0 313 808 09/20/88 Europe 37 22 984 01/19/89 BN Germany BO 0 142 339 04/26/89 Europe BP 108 588 06/28/89 Europe OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.) BO Dern et al., "Studies on the preservation of human blood. II. The relationship of erythrocyte adenosine triphosphate levels and other in vitro measures to red cell storageability", J. Lab. & Clin. Med., Vol. 69, No. 6, 1967, pp. 968-978. BR Funder et al., "Chloride and Hydrogen Ion Distribution between Human Red Cells and Plasma", Acta Physiol. Scand., Vol. 68, 1966, pp. 234-245. Griffin, B. et al., "Studies on the Procurement of Blood Coagulation Factor VIII," Vox BS Sang., 55:9-13 (1988). BT Harmening et al, "The Use of Ion-Exchange Resins as a Blood Preservation System", Transfusion, Vol. 19, No. 6, 1979, pp. 675-681. BU Högman et al., "The Bottom and Top System: A New Technique for Blood Component Preparation and Storage", Vox Sang, Vol. 55, 1988, pp. 211-217. BV Högman et al., "Red Cell Suspensions in SAGM Medium", Vox Sang, Vol. 45, 1983, pp. 217-223.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication t applicant.

Date Considered

RADENAS

37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT

(use several sheets if necessary)

Docket No. Serial No. F-4066 DIV-CONT-DIV II 10/608,200 Applicant

Payrat et al.

Group Art Unit

		(use several sheets if	necessary)					
	(and solvering interesting)				Filing Date June 27, 2003		Group Art Un Unknown	
		U.5	S. PATENI	DOCUMENTS	•			
Examiner's Initials		Document Number	Date	Name	Class	Subclass		ng Date
	CA	4,994,046	02/19/91	Ikeda				
	СВ	4,994,057	02/19/91	Carmen et al.				
	CC	4,997,083	03/05/91	Loretti et al.				
	CD	5,019,432	05/28/91	Kawamura et al.				
	CE	5,079,002	01/07/92	Nagai et al.				
	CF	5,248,506	09/28/93	Holme et al.				
	CG	5,250,303	10/05/93	Meryman et al.				
	CH	5,494,590	02/27/96	Smith et al.				
	CI					_		
	C							
	CK							
		FOREI	GN PATEN	T DOCUMENTS			1	
		Document Number	Date	Country	Class	Subclass	Tran Yes	slation No
	CL	WO 91/04659	04/18/91	PCT		•	103	110
	СМ	0 099 315	02/22/84	Europe				
	CN	0 152 719	12/09/81	Netherlands				
	СО	1106826	04/89	Japan				
	CP	WO 98/09660	03/12/98	PCT				
	O	THER ART (Includin	g Author, 7	litle, Date, Pertine	nt Pages.	Etc.)	1	
	CQ	LaCelle et al., "The Pa of General Physiology	assive Perme	ability of the Red B			The Jo	urnal
	CR	Matsuyama et al., "Lack of Success with a Combination of Alanine and Phosphoenolpyruvate as an Additive for Liquid Storage of Red Cells at 4°C," Transfusion, Vol. 30, No. 4, 1990, pp. 339-343. Meryman, H.T., "Extended Storage of Washed Red Cells at 4°C," Abstract -14th International Symposium on Blood Transfusion. Meryman, H.T., "Prolonged Storage of Red Cells at 4°C," Transfusion, Vol. 26, No. 6, 1986, pp. 500-505.						
	CS							
	СТ							6,
	CU	Messeter et al., "CPD- Chemical Abstracts, V pp. 210-217.	Adenine as a ol. 87, No. 1	a Blood Preservative 13, 1977, #99582X a	Studies and in <i>Tra</i>	in vitro and in sfusion, Vol	n vivo, . 17., N	" Vo. 3,
	CV	Mezy et al., "Study and Abstracts, Vol. 89, N Hung, Vol. 48, N . 4,	. 19, 1978, <i>A</i>	Abstract #16084W as	nosine Blo nd in Absi	ood Stabiliser tract and Acto	" Chen	nical n.
xaminer			Date Consid	lered	•		*	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communicati n t applicant.

OCT 0 8 2063

37 CFR 1.501 INFORMATION DISCLOSURE STATEMENT IN A PATENT

(use several sheets if necessary)

Docket No.
F-4066 DIV-CONT-DIV II 10/608,200

Applicant
Payrat et al.

Filing Date

Group Art Unit

			Filing Date June 27, 2003	Group Art Unit Unknown		
	ОТН	ER PRIOR ART (Including Author, Title, Date, Pe	ertinent Pages, Etc.)	.		
	DA	Mishler, J.M. et al., "Whole Blood Storage in Citrate Half-Strength Trisdoium Citrate-Cellular and Bio Pathology, Vol. 124, No. 3, pp. 125-139.	and Phosphate Solution	ns Containing e Journal of		
	DB	Moore et al., "Ascorbate-2-phosphate in red cell pr components", Transfusion, Vol. 28, No. 3, 1988, pp.		als and active		
	DC	Moroff et al., "Proposed standardization of methods for stored red cells", <i>Transfusion</i> , Vol. 24, No. 2, 1984, p		ur survival f		
	DD	Napier, J.A.F. et al., "What is the 'Optimum' Optim 49:315-218 (1985).	nal Additive Solution?	, Vox Sang.,		
	DE	Prowse, C. et al., "Studies on the Procurement of Blo Stuides on Blood Components Prepared in Half-Streng 52:257-264 (1987).				
	DF	Robertson, "Macroaggregate Formation in Optimal Add 266 (1985).	ditive Red Cells," Vox Se	ang., 49:259-		
	DG	Rock et al., "In Vivo Effectiveness of a High-Yield F Blood Bank", The New England Journal of Medicine (1984).				
	DH	Strauss et al., "SAG-Sucrose Medium for Red Bloch Abstracts, Vol. 106, No. 17, 1987, Abstract #1360092 46, No. 2-3, pp. 295-299.	-	6.1		
	DI	Tsuboi, "Regulation of Erythrocyte Glycolysis Membr Low-Electrolyte Medium", Biochimica et Biophysica				
	DJ	Tsuda et al., "Intracellular pH of Red Cells Stored i Specialia, Experientia 28/12, 1972, pp. 1481-1482.	in Acid Citrate Dextros	se Medium",		
	DK	Valeri et al., "Viability and Function of Red Blood Cell Concentrates Stored at 4°C for 35 Days in CPDA-1, CPDA-2, or CPDA-3," <i>Transfusion</i> , Vol. 22, No. 3, 1982, pp. 210-216.				
	DL	Vora et al., "The effect of additives on red cell 2,3 diphosphoglycerate levels in CPDA preservatives", <i>Transfusion</i> , Vol. 29, No. 3, 1989, pp. 226-229.				
	DM	Wood et al., "Storage of Erythrocytes in Artificial Media", Transfusion, Vol. 11, No. 3, 1971, pp. 123-133.				
	DN	Decision in Appeal No. 93-3239 - February 28, 1994				
	DO	Decision in Appeal No. 2002-0090 - Ap	oril 30. 2003			
	DP					
	DQ					
Examiner		Date Considered	-			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy f this form with next communication to applicant.